Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Glycerol Phenylbutyrate (Ravicti) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
- AE
adverse event
- ANOVA
analysis of variance
- ASS
argininosuccinate synthetase
- BRIEF
Behavior Rating Inventory of Executive Function
- CBCL
Child Behavior Checklist
- CI
confidence interval
- CORD
Canadian Organization for Rare Disorders
- CPS1
carbamoyl phosphate synthetase 1
- CVLT-II
California Verbal Learning Test
- DB
Double blind
- GI
gastrointestinal
- GPB
glycerol phenylbutyrate
- HAC
hyperammonemic crises
- HC
Health Canada
- HRQoL
health-related quality of life
- ITT
intention-to-treat
- IQ
intelligence quotient
- NaPBA
sodium phenylbutyrate
- OTC
ornithine transcarbamylase
- PedsQL SF15
Pediatric Quality of Life Inventory Generic Core Scales SF15 (short form 15)
- PP
per-protocol
- QoL
quality of life
- RCT
randomized controlled trial
- SAE
serious adverse event
- SD
standard deviation
- SF-36
Short Form (36) Health Survey
- TNAUC
time-normalized area under the curve
- UCD
urea cycle disorder
- ULN
upper limit of normal
- WASI-II
Wechsler Abbreviated Scale of Intelligence
- WPPSI-III
Wechsler Preschool and Primary Scale of Intelligence
- ABBREVIATIONS - Glycerol Phenylbutyrate (Ravicti)ABBREVIATIONS - Glycerol Phenylbutyrate (Ravicti)
- Clinical Evidence - Clinical Review Report: Icosapent Ethyl (Vascepa)Clinical Evidence - Clinical Review Report: Icosapent Ethyl (Vascepa)
- CLINICAL DATA USED IN REANALYSIS - Glycerol Phenylbutyrate (Ravicti)CLINICAL DATA USED IN REANALYSIS - Glycerol Phenylbutyrate (Ravicti)
- ISSUES FOR CONSIDERATION - Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day)ISSUES FOR CONSIDERATION - Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day)
- SUMMARY OF MANUFACTURER’S SENSITIVITY ANALYSES - Ustekinumab (Stelara)SUMMARY OF MANUFACTURER’S SENSITIVITY ANALYSES - Ustekinumab (Stelara)
Your browsing activity is empty.
Activity recording is turned off.
See more...